Immunotherapy of immunosenescence: who, how and when?

Détails

ID Serval
serval:BIB_B26998B57C5F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Immunotherapy of immunosenescence: who, how and when?
Périodique
Open Longevity Science
Auteur⸱e⸱s
Govind  Sheila, Lapenna  Antonio, Lang1  Pierre Olivier, Aspinall  Richard
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
6
Pages
56-63
Langue
anglais
Notes
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License
Résumé
Major changes in social welfare, economic conditions and medical knowledge over the last 60 years have produced
a demographic shift in the population. More individuals are living longer, and in a decade there will be more people
over 65 than infants under 5 for the first time in history. Taking the analysis beyond mere numbers reveals that older individuals
are now physically more active than their forebears and travel more widely. This provides a greater opportunity
for encountering infectious agents which could present a considerable problem. Older individuals are more susceptible to
infection and do not respond as well as younger people to vaccination because of an age related decline in immunity, a
state which has been termed immunosenesence. This decline is not uniform and some older individuals show a greater decline
in their immune response than others. In this review we have sought to consider who are the 'at risk' individuals,
how they might best be treated and when.
Création de la notice
15/04/2015 10:25
Dernière modification de la notice
20/08/2019 16:21
Données d'usage